benzyl-3,3-dimethyl-5-hexenoate | 87995-46-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl-3,3-dimethyl-5-hexenoate
• 英文别名: Benzyl 3,3-dimethylhex-5-enoate
• CAS: 87995-46-8
• 化学式: C₁₅H₂₀O₂
• 分子量: 232.323
• InChiKey: SANPSUOFCYKTQQ-UHFFFAOYSA-N

物化性质

• 沸点：
  309.3±21.0 °C(Predicted)
• 密度：
  0.982±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯基甲基3-甲基丁-2-烯酸酯 、 alkaline earth salt of/the/ methylsulfuric acid 以27%的产率得到benzyl-3,3-dimethyl-5-hexenoate
  参考文献：
  名称：

  烯丙基硅烷与迈克尔受体共轭加成中的化学选择性

  摘要：

  通过用氟离子处理烯丙基硅烷而生成的烯丙基碳负离子要经历高度化学选择性的共轭加成反应，添加到一系列迈克尔受体上，对于这些受体，其他已知的烯丙基化方法被证明不那么普遍。

  DOI：

  10.1016/s0040-4039(00)81803-1

文献信息

• Hydroxyl compounds and compositions for cholesterol management and related uses
  申请人：Esperion Therapeutics Inc.

  公开号：EP2402300A1

  公开（公告）日：2012-01-04

  The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  g.,X综合征）、血栓性疾病。本发明的化合物和方法还可用于调节 C 反应蛋白或提高患者的胆汁分泌。在某些实施方案中，本发明的化合物、组合物和方法可与其他治疗药物（如降胆固醇药和降血糖药）联合使用。
• MAJETICH G.; CASARES A.; CHAPMAN D.; BEHNKE M., J. ORG. CHEM., 51,(1986) N 10, 1745-1753
  作者：MAJETICH G.、 CASARES A.、 CHAPMAN D.、 BEHNKE M.

  DOI：——

  日期：——
• Chemoselectivity in the conjugate addition of allylsilane to Michael acceptors
  作者：George Majetich、Ada M. Casares、D. Chapman、M. Behnke

  DOI：10.1016/s0040-4039(00)81803-1

  日期：1983.1

  The allylic carbanion species generated by treatment of allylsilane with fluoride ion undergoes highly chemoselective conjugate addition to a series of Michael acceptors for which alternative known allylation procedures proved less general.

  通过用氟离子处理烯丙基硅烷而生成的烯丙基碳负离子要经历高度化学选择性的共轭加成反应，添加到一系列迈克尔受体上，对于这些受体，其他已知的烯丙基化方法被证明不那么普遍。